57/100BElevance Health stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Elevance Health is 466.69, 9.6% above the current price of 425.80. Their targets range from 395.00 to 523.00.
Of the 19 firms that rated Elevance Health in the past 12 months, 14 rate it buy or strong buy, 5 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 395.00 to 523.00, with an average of 466.69.
| Buy | 14 | |
| Hold | 5 | |
| Sell | 0 |
12-month price target
| Highest target | 523.00 |
| Average target | 466.69 |
| Lowest target | 395.00 |
| Current price | 425.80 |
Elevance Health price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Elevance Health price target and rating?
How analysts rate Elevance Health, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
14 of 19 firms rate it buy now, against 10 of 16 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Elevance Health analyst upgrades, downgrades and price targets
The latest rating change came on 20 May 2026, when Deutsche Bank upgraded Elevance Health from Hold to Buy. Its price target is 498.00, from 332.00. The most recent new target came from Piper Sandler on 23 October 2026: 520.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 23 Oct 2026 | Piper Sandler | — | 409.00 → 520.00 | +27.1% | 442.85 |
| 23 Oct 2026 | Mizuho Securities Ann Hynes | — | 465.00 → 490.00 | +5.4% | 445.28 |
| 23 Oct 2026 | Goldman Sachs | — | 395.00 → 451.00 | +14.2% | 445.28 |
| 22 Oct 2026 | UBS | Reiterated · Buy | 460.00 → 523.00 | +13.7% | 439.10 |
| 22 Oct 2026 | RBC Capital | Reiterated · Sector Perform | 424.00 → 455.00 | +7.3% | 441.21 |
| 22 Oct 2026 | Guggenheim Jason Cassorla | Reiterated · Buy | 460.00 → 485.00 | +5.4% | 434.13 |
| 22 Oct 2026 | Robert W. Baird | — | 393.00 → 406.00 | +3.3% | 434.13 |
| 22 Oct 2026 | Barclays | Reiterated · Overweight | 469.00 → 472.00 | +0.6% | 434.13 |
| 12 Oct 2026 | Guggenheim Jason Cassorla | Reiterated · Buy | 455.00 → 460.00 | +1.1% | 412.70 |
| 7 Oct 2026 | Barclays | Reiterated · Overweight | 457.00 → 469.00 | +2.6% | 400.09 |
| 17 Jul 2026 | Leerink Partners | Reiterated · Market Perform | 364.00 → 395.00 | +8.5% | 369.28 |
| 16 Jul 2026 | Bernstein | — | 482.00 → 488.00 | +1.2% | 372.85 |
| 16 Jul 2026 | New Street | — | 482.00 | — | 377.63 |
| 16 Jul 2026 | RBC Capital | Reiterated · Sector Perform | 439.00 → 424.00 | -3.4% | 390.33 |
| 16 Jul 2026 | Goldman Sachs | — | 343.00 → 395.00 | +15.2% | 390.33 |
| 16 Jul 2026 | Robert W. Baird | — | 331.00 → 393.00 | +18.7% | 390.33 |
| 16 Jul 2026 | Guggenheim | Reiterated · Buy | 399.00 → 455.00 | +14.0% | 390.33 |
| 16 Jul 2026 | Wells Fargo Stephen Baxter | Reiterated · Overweight | 492.00 → 473.00 | -3.9% | 390.33 |
| 16 Jul 2026 | Barclays | Reiterated · Overweight | 480.00 → 457.00 | -4.8% | 390.33 |
| 14 Jul 2026 | Truist Financial | Reiterated · Buy | 450.00 → 475.00 | +5.6% | 425.17 |
| 13 Jul 2026 | Wells Fargo | Reiterated · Overweight | 391.00 → 492.00 | +25.8% | 416.23 |
| 9 Jul 2026 | RBC Capital Ben Hendrix | Reiterated · Sector Perform | 358.00 → 439.00 | +22.6% | 425.90 |
| 7 Jul 2026 | Raymond James Sarah James | — | 450.00 | — | 408.17 |
| 2 Jul 2026 | Bernstein | Reiterated · Outperform | 409.00 → 482.00 | +17.8% | 416.19 |
| 8 Jun 2026 | Mizuho Securities | Reiterated · Outperform | 435.00 → 465.00 | +6.9% | 415.53 |
| 4 Jun 2026 | Morgan Stanley | Reiterated · Equal Weight | 352.00 → 404.00 | +14.8% | 391.27 |
| 1 Jun 2026 | Truist Financial David MacDonald | Reiterated · Buy | 390.00 → 450.00 | +15.4% | 393.19 |
| 26 May 2026 | Barclays Andrew Mok | Reiterated · Overweight | 408.00 → 480.00 | +17.6% | 386.87 |
| 22 May 2026 | UBS | Reiterated · Buy | 400.00 → 460.00 | +15.0% | 389.82 |
| 20 May 2026 | Mizuho Securities | Reiterated · Outperform | 350.00 → 435.00 | +24.3% | 402.27 |
| 20 May 2026 | Deutsche Bank | Upgraded · Hold → Buy | 332.00 → 498.00 | +50.0% | 402.27 |
| 29 Apr 2026 | B of A Securities | Upgraded · Neutral → Buy | — | — | — |
| 24 Apr 2026 | Guggenheim | Reiterated · Buy | 396.00 → 399.00 | +0.8% | 346.29 |
| 24 Apr 2026 | Barclays | Reiterated · Overweight | 393.00 → 408.00 | +3.8% | 346.29 |
| 23 Apr 2026 | Leerink Partners | — | 364.00 | — | 346.21 |
| 23 Apr 2026 | Robert W. Baird | — | 331.00 | — | 328.20 |
| 20 Apr 2026 | Jefferies David Windley | Reiterated · Buy | 391.00 | — | 323.05 |
| 10 Mar 2026 | Mizuho Securities Ann Hynes | — | 413.00 → 350.00 | -15.3% | 282.68 |
| 3 Feb 2026 | RBC Capital | — | 358.00 | — | 341.83 |
| 2 Feb 2026 | Truist Financial | Reiterated · Buy | 400.00 → 390.00 | -2.5% | 341.29 |
| 2 Feb 2026 | Craig-Hallum | — | 409.00 | — | 340.68 |
| 2 Feb 2026 | Piper Sandler | — | 409.00 | — | 340.68 |
| 1 Feb 2026 | Bernstein | — | 431.00 → 409.00 | -5.1% | 345.74 |
| 30 Jan 2026 | Wells Fargo | Reiterated · Overweight | 424.00 → 391.00 | -7.8% | 346.98 |
| 30 Jan 2026 | Barclays | Reiterated · Overweight | 404.00 → 393.00 | -2.7% | 346.98 |
| 29 Jan 2026 | UBS | — | 400.00 | — | 345.27 |
| 29 Jan 2026 | Deutsche Bank | — | 320.00 → 332.00 | +3.8% | 345.22 |
| 29 Jan 2026 | Guggenheim Jason Cassorla | Reiterated · Buy | 414.00 → 396.00 | -4.3% | 341.85 |
| 22 Jan 2026 | Guggenheim Jason Cassorla | Reiterated · Buy | 398.00 → 414.00 | +4.0% | 369.88 |
| 9 Jan 2026 | Mizuho Securities Ann Hynes | — | 400.00 → 413.00 | +3.2% | 374.77 |
Elevance Health EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Elevance Health's EPS to grow 11.3% a year until 2028, faster than over the last 5 years (6.9% a year) and the last 3 years (1.1%).
Analysts expect Elevance Health's revenue to grow 2.3% a year until 2028, slower than over the last 5 years (10.3% a year) and the last 3 years (8.3%).
Revenue
EPS
Does Elevance Health beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 11.5% off the result, either way, and their revenue estimate 2.1%, over the last 12 quarters.
- EPS beats
- 84 / 100
- Revenue beats
- 83 / 100
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +9.1%
- Since
- February 2002
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 21 Oct 2026 | 4.71 | 6.99 | +48.4% | 49.28B | 50.44B | +2.4% |
| Q2 FY2026 | 15 Jul 2026 | 6.21 | 7.45 | +20.0% | 48.88B | 49.83B | +1.9% |
| Q1 FY2026 | 22 Apr 2026 | 10.82 | 12.58 | +16.3% | 48.20B | 49.49B | +2.7% |
| Q4 FY2025 | 28 Jan 2026 | 3.10 | 3.33 | +7.4% | 49.84B | 49.31B | -1.1% |
| Q3 FY2025 | 21 Oct 2025 | 4.93 | 6.03 | +22.3% | 49.38B | 50.09B | +1.4% |
| Q2 FY2025 | 17 Jul 2025 | 8.91 | 8.84 | -0.8% | 48.19B | 49.42B | +2.6% |
| Q1 FY2025 | 22 Apr 2025 | 11.41 | 11.97 | +4.9% | 46.30B | 48.77B | +5.3% |
| Q4 FY2024 | 23 Jan 2025 | 3.80 | 3.84 | +1.1% | 44.95B | 45.44B | +1.1% |
| Q3 FY2024 | 17 Oct 2024 | 9.66 | 8.37 | -13.4% | 43.47B | 45.15B | +3.9% |
| Q2 FY2024 | 17 Jul 2024 | 10.01 | 10.12 | +1.1% | 42.99B | 43.65B | +1.5% |
| Q1 FY2024 | 18 Apr 2024 | 10.53 | 10.64 | +1.0% | 42.49B | 42.58B | +0.2% |
| Q4 FY2023 | 24 Jan 2024 | 5.55 | 5.62 | +1.3% | 42.09B | 42.65B | +1.3% |
Elevance Health stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Elevance Health's earnings keep growing at the 4.7% a year analysts expect to FY2028, it would earn about 37.94 a share in FY2030. At the P/E it has traded at over the last five years (13.9 to 20.9) that is 528.23 to 792.48 a share, or 658.77 at its average P/E of 17.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 29.05 | 404.44 | 504.38 | 606.76 |
| FY2027 | 30.25 | 421.11 | 525.18 | 631.78 |
| FY2028 | 34.62 | 481.95 | 601.05 | 723.05 |
| FY2029 (extrapolated) | 36.24 | 504.56 | 629.25 | 756.97 |
| FY2030 (extrapolated) | 37.94 | 528.23 | 658.77 | 792.48 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 4.7% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (13.9, 17.4, 20.9).
Is Elevance Health stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Elevance Health's P/E of 18.1 is above the middle of its 5-year range (11.2 to 21.4, median 17.1). Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history. Buyers pay less for each point of growth than usual: a PEG of 1.6 on expected growth against 2.5 on its median P/E and past five years' growth. At its usual P/E (17.1 × EPS of 23.48), Elevance Health's fair value is 401.93; the price, 425.80, is 5.9% above it. Its forward P/E, on the consensus for FY2026, is 14.7.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (11.2 and 21.4). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 18.13
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.12
- Five-year P/E range
- 11.2 – 21.4
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 14.66
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.87
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +9.6%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.